Search Results - "Gertz, M"

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond by Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C

“…Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM…”
Get full text

Systemic amyloidosis from A (AA) to T (ATTR): a review by Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., Kumar, S. K., Gertz, M. A.

“…Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to progressive organ failure. There are over 15 types of systemic…”
Get full text

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis by Comenzo, R L, Reece, D, Palladini, G, Seldin, D, Sanchorawala, V, Landau, H, Falk, R, Wells, K, Solomon, A, Wechalekar, A, Zonder, J, Dispenzieri, A, Gertz, M, Streicher, H, Skinner, M, Kyle, R A, Merlini, G

“…This manuscript summarizes the recommendations that emerged from the first Roundtable on Clinical Research in Immunoglobulin Light-chain Amyloidosis (AL), a…”
Get full text

Effect of sample size and length of observation period on the reliability of apparent pig organ lesion prevalence by Gertz, M., Krieter, J.

“…Comprehensive identification of on-farm animal-health issues still requires extensive efforts so that in practice such monitoring is applied only sparsely. An…”
Get full text

Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke by Elgendy, Akram Y, Saver, Jeffrey L, Amin, Zahid, Boudoulas, Konstantinos Dean, Carroll, John D, Elgendy, Islam Y, Grunwald, Iris Q, Gertz, Zachary M, Hijazi, Ziyad M, Horlick, Eric M, Kasner, Scott E, Kent, David M, Kumar, Preetham, Kavinsky, Clifford J, Liebeskind, David S, Lutsep, Helmi, Mojadidi, Mohammad K, Messé, Steven R, Mas, Jean-Louis, Mattle, Heinrich P, Meier, Bernhard, Mahmoud, Ahmad, Mahmoud, Ahmed N, Nietlispach, Fabian, Patel, Nimesh K, Rhodes, John F, Reisman, Mark, Sommer, Robert J, Sievert, Horst, Søndergaard, Lars, Zaman, Muhammad O, Thaler, David, Tobis, Jonathan M

“…Recent epidemiologic and therapeutic advances have transformed understanding of the role of and therapeutic approach to patent foramen ovale (PFO) in ischemic…”
Get more information

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents by Majithia, N, Rajkumar, S V, Lacy, M Q, Buadi, F K, Dispenzieri, A, Gertz, M A, Hayman, S R, Dingli, D, Kapoor, P, Hwa, L, Lust, J A, Russell, S J, Go, R S, Kyle, R A, Kumar, S K

“…Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem…”
Get full text

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis by Gertz, M A, Lacy, M Q, Dispenzieri, A, Kumar, S K, Dingli, D, Leung, N, Hogan, W J, Buadi, F K, Hayman, S R

“…This study sought to develop selection guidelines to determine the eligibility for SCT of patients with light-chain amyloidosis. Patients with biopsy-confirmed…”
Get full text

Marked changes in right ventricular contractile pattern after cardiothoracic surgery: Implications for post-surgical assessment of right ventricular function by Raina, Amresh, MD, Vaidya, Anjali, MD, Gertz, Zachary M., MD, Susan Chambers, CRNP, Forfia, Paul R., MD

“…Background Longitudinal shortening accounts for the majority of right ventricular (RV) contraction in normal hearts. This finding accounts for the correlation…”
Get full text

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients by Kumar, S K, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Pandey, S, Kapoor, P, Dingli, D, Hayman, S R, Leung, N, Lust, J, McCurdy, A, Russell, S J, Zeldenrust, S R, Kyle, R A, Rajkumar, S V

“…Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have…”
Get full text

Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement by Ebraheem, M S, Gertz, M, Mian, H

“…Despite significant advancements in multiple myeloma (MM) treatment, including novel therapies and combination strategies, the translation of findings from…”
Get full text

Genetic aberrations and survival in plasma cell leukemia by Tiedemann, R E, Gonzalez-Paz, N, Kyle, R A, Santana-Davila, R, Price-Troska, T, Van Wier, S A, Chng, W J, Ketterling, R P, Gertz, M A, Henderson, K, Greipp, P R, Dispenzieri, A, Lacy, M Q, Rajkumar, S V, Bergsagel, P L, Stewart, A K, Fonseca, R

“…Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic…”
Get full text

How to manage primary amyloidosis by Gertz, M A

“…Immunoglobulin light chain amyloidosis is a protein deposition disorder where the precursor protein represents a monoclonal immunoglobulin light or heavy…”
Get full text

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma by KUMAR, S, DISPENZIERI, A, GERTZ, M. A, LACY, M. Q, HAYMAN, S. R, BUADI, F. K, GASTINEAU, D. A, LITZOW, M. R, FONSECA, R, ROY, V, RAJKUMAR, S. V

“…While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell…”
Get full text

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center by Dispenzieri, A, Seenithamby, K, Lacy, M Q, Kumar, S K, Buadi, F K, Hayman, S R, Dingli, D, Litzow, M R, Gastineau, D A, Inwards, D J, Micallef, I N, Ansell, S M, Johnston, P B, Porrata, L F, Patnaik, M M, Hogan, W J, Gertz, M A A

“…The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of ‘tumor burden’ but…”
Get full text

Alterations in sick dairy cows’ daily behavioural patterns by Dittrich, I., Gertz, M., Krieter, J.

“…The recent development of dairy production is characterised by increasing herd sizes and therefore increasingly complicated visual observation of cow…”
Get full text

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design by Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.

Get full text

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design by Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.

Get full text

International uniform response criteria for multiple myeloma by DURIE, B. G. M, HAROUSSEAU, J.-L, LUDWIG, H, GAHRTON, G, BEKSAC, M, CROWLEY, J, BELCH, A, BOCCADARO, M, TURESSON, I, JOSHUA, D, VESOLE, D, KYLE, R, MIGUEL, J. S, ALEXANIAN, R, TRICOT, G, ATTAL, M, MERLINI, G, POWLES, R, RICHARDSON, P, SHIMIZU, K, TOSI, P, MORGAN, G, RAJKUMAR, S. V, BLADE, J, BARLOGIE, B, ANDERSON, K, GERTZ, M, DIMOPOULOS, M, WESTIN, J, SONNEVELD, P

“…New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow…”
Get full text

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma by Dispenzieri, A, Tong, C, LaPlant, B, Lacy, M Q, Laumann, K, Dingli, D, Zhou, Y, Federspiel, M J, Gertz, M A, Hayman, S, Buadi, F, O'Connor, M, Lowe, V J, Peng, K-W, Russell, S J

“…MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter—a means for monitoring by non-invasive imaging of…”
Get full text

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) by Lacy, M Q, Hayman, S R, Gertz, M A, Short, K D, Dispenzieri, A, Kumar, S, Greipp, P R, Lust, J A, Russell, S J, Dingli, D, Zeldenrust, S, Fonseca, R, Bergsagel, P L, Roy, V, Mikhael, J R, Stewart, A K, Laumann, K, Allred, J B, Mandrekar, S J, Rajkumar, S V, Buadi, F

“…Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has…”
Get full text